Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Original Publication Date
Article Source
External Web Content
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration…
